IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2045

Conditions

High-grade Glioma

Interventions

BIOLOGICAL

Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells

Single dose of 8R-70CAR T cells administered IV

Trial Locations (1)

RECRUITING

University of Florida Health Children's Hospital, Gainesville

All Listed Sponsors

collaborator

Florida Department of Health

OTHER_GOV

lead

University of Florida

OTHER